logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
NGNE
Neurogene Inc.
32.09
2 x 25.99
2 x 44.63
bid
ask
-
0.32
0.99%
2 @ 07:30 PM
32.09 +0.00 (0.00%)
Ytd55.78%
1y71.79%
31.89
day range
33.15
16.37
52 week range
42.84
Open32.49Prev Close32.41Low31.89High33.15Mkt Cap642.17M
Vol1.39MAvg Vol237.43KEPS-5.04P/EN/AForward P/E-4.85
Beta1.69Short Ratio7.15Inst. Own110.72%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg36.63200-d Avg26.721yr Est52.80

NGNE News

Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
defenseworld.net
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE

Bank of New York Mellon Corp acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) duri

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
businesswire.com
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
defenseworld.net
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE

BlackRock Inc. acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) in the undefined q
benzinga.com
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166

Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers th
benzinga.com
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises t
benzinga.com
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy a

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
gurufocus.com
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medic
benzinga.com
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst cons

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
businesswire.com
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici

Neurogene Inc. Announces Pricing of $125 Million Public Offering
businesswire.com
Neurogene Inc. Announces Pricing of $125 Million Public Offering

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
Neurogene Reveals Proposed Public Offering; No Size Disclosed

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici

Neurogene Inc. Announces Proposed Public Offering
businesswire.com
Neurogene Inc. Announces Proposed Public Offering

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
seekingalpha.com
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Tra

Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Tra

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
gurufocus.com
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medic
benzinga.com
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For T

47 total developmental milestones gained across 10 participants, with durable treatment effect and n

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
gurufocus.com
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medic
benzinga.com
Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to str

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
businesswire.com
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.39) per share which missed the analyst cons

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
businesswire.com
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
businesswire.com
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
businesswire.com
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targe

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180

Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers th
benzinga.com
Neurogene Q4 EPS $(1.13), Inline

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.13) per share which met the analyst consens

Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-M

U.S. stock futures lower, Dow futures down 1%. Yatsen Holding shares fall 10.1%, while other stocks

benzinga.com
Canaccord Genuity Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $200

Canaccord Genuity analyst Whitney Ijem initiates coverage on Neurogene (NASDAQ:NGNE) with a Buy r

Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
benzinga.com
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results

U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares

Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday
benzinga.com
Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday

Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gain

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy
benzinga.com
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy

Neurogene stock jumps after FDA grants Breakthrough Therapy status to NGN-401 for Rett syndrome trea

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premark

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
LifeSci Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $5

LifeSci Capital analyst Patrick Dolezal initiates coverage on Neurogene (NASDAQ:NGNE) with a Outp
benzinga.com
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy

benzinga.com
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $70

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy a
benzinga.com
Neurogene Announces Updated Interim Clinical Study In Pediatric Group From Its Current Phase 1/2 Tri

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medic

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
benzinga.com
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty i

Apple To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
Apple To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $65

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy a
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $45 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy